[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese Medical Association\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":149},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,71,92,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100651038","personalized-nutritional-formula-for-icu-patients-a-study-on-prognosis-and-multidimensional-health-markers-100651038",false,"NCT07755033","Personalized Nutritional Formula for ICU Patients: A Study on Prognosis and Multidimensional Health Markers","The Effect of an Individualized Nutrition Formula on Clinical Prognosis, Intestinal and Pulmonary Microbiota, Serum Metabolomics, and Macronutrient Balance in Critically Ill Patients: A Prospective Interventional Study","Inclusion Criteria:\n\nCritically ill patients admitted to the intensive care unit (ICU) who meet the indications for enteral nutrition support.\n\nAge ≥ 18 years. APACHE II score \\> 8 at ICU admission. Expected ICU length of stay \\> 7 days.\n\nExclusion Criteria:\n\nAge \\\u003C 18 years. Pregnancy or lactation. Known allergy to any component of the enteral nutrition formula. Gastrointestinal bleeding, incomplete intestinal obstruction, or other conditions precluding full enteral nutrition.\n\nKnown severe thyroid dysfunction (e.g., thyrotoxic crisis, myxedema coma, or uncontrolled hyperthyroidism\u002Fhypothyroidism).\n\nChronic end-stage organ failure, including: New York Heart Association (NYHA) Class IV heart failure, Child-Pugh Class C cirrhosis, or Stage 5 chronic kidney disease (CKD).\n\nPrimary intestinal diseases (e.g., Crohn's disease, ulcerative colitis, or intestinal malignancies), short bowel syndrome, or history of extensive small bowel resection (residual small intestine \\\u003C 100 cm).\n\nMetabolic disorders that significantly affect nutritional metabolism (e.g., Sheehan's syndrome, or other conditions with major metabolic consequences) as determined by the investigator.","ALL","18 Years",{"count":19,"type":20},1200,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the effects of an individualized enteral nutrition formula on clinical outcomes in critically ill adult patients in the intensive care unit (ICU). Participants will be randomly assigned to one of two groups: the individualized nutrition group or the standard nutrition group. In the individualized group, the total daily amount of enteral nutrition will be calculated and adjusted daily based on the patient's resting energy expenditure (measured by indirect calorimetry) and serum protein levels. In the standard group, a fixed-dose formula will be administered according to routine clinical protocols recommended by current guidelines. The intervention will be initiated within 48 hours of ICU admission and continued for up to 14 days or until ICU discharge. The study will assess clinical prognosis, as well as changes in gut and pulmonary microbiota, serum metabolomics, and macronutrient balance. The findings may provide evidence for personalized nutrition strategies in critically ill patients.",[26,27,28],"Sepsis","Nutrition","Gut -Microbiota",[30],"Critical Illness","NOT_YET_RECRUITING","2026-08-05",{"date":34,"type":35},"2026-08-10","ACTUAL",{"date":37,"type":20},"2026-07-28",{"date":39,"type":20},"2028-12-31",{"name":41,"class":42},"Chinese Medical Association","NETWORK",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100625058","phase-4-palmitoleic-acid-combined-with-infliximab-for-promoting-intestinal-mucosal-healing-in-crohns-disease-100625058","NCT07417696","Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","A Randomized, Controlled Trial Investigating the Efficacy of Palmitoleic Acid Combined With Infliximab in Promoting Intestinal Mucosal Healing in Patients With Crohn's Disease","Inclusion Criteria:\n\n1. Adult patients aged 18 to 75 years.\n2. Established diagnosis of Crohn's disease confirmed by radiologic, histologic, or endoscopic evidence.\n3. Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).\n4. Adequate cardiac, renal, and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.\n5. Willingness and ability to provide written informed consent.\n6. Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.\n\nExclusion Criteria:\n\n1. Use of any biologic therapy (e.g., infliximab, adalimumab, ustekinumab, vedolizumab) within 8 weeks prior to screening.\n2. Use of supplements containing fish oil or other lipid supplements (e.g., macadamia oil, krill oil, flaxseed, primrose oil, sea buckthorn oil) within 8 weeks prior to screening.\n3. History of any intestinal resection or other Crohn's disease-related surgery.\n4. History of or active chronic or recurrent infectious disease.\n5. History of or current malignancy.\n6. Pregnancy, lactation, or intention to become pregnant during the study period.\n7. Known hypersensitivity to infliximab or palmitoleic acid preparations.","75 Years",{"count":52,"type":20},400,[54],"PHASE4","This study aims to evaluate whether the combination of palmitoleic acid with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.",[57],"Crohn's Disease",[59,60,61,62],"Infliximab","Palmitoleic acid","Mucosal healing","Inflammatory bowel disease","2026-02-11",{"date":65,"type":35},"2026-02-18",{"date":67,"type":20},"2026-04-01",{"date":69,"type":20},"2029-03-31",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":4},"100624887","phase-4-akkermansia-muciniphila-combined-with-infliximab-for-promoting-intestinal-mucosal-healing-in-crohns-disease-100624887","NCT07415473","Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","A Randomized, Controlled Trial Investigating the Efficacy of Akkermansia Muciniphila Combined With Infliximab in Promoting Intestinal Mucosal Healing in Patients With Crohn's Disease","Inclusion Criteria:\n\n1. Adult patients aged 18 to 75 years.\n2. Documented diagnosis of Crohn's disease established at any time prior to screening by radiological, histological, or endoscopic evidence.\n3. Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).\n4. Adequate cardiac, renal and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.\n5. Willingness and ability to provide written informed consent.\n6. Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.\n\nExclusion Criteria:\n\n1. Use of any biologic therapy (e.g., infliximab, adalimumab, ustekinumab, vedolizumab) within 8 weeks prior to screening.\n2. Use of systemic antibiotics or any probiotic preparation within 4 weeks prior to screening.\n3. History of any intestinal resection or other Crohn's disease-related surgery.\n4. History of or active chronic or recurrent infectious disease.\n5. History of or current malignancy.\n6. Pregnancy, lactation, or intention to become pregnant during the study period.",{"count":52,"type":20},[54],"This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.",[82],"Crohn's Diseases",[61,59,84,85,62],"Akkermansia muciniphila","Probiotics","2026-02-10",{"date":88,"type":35},"2026-02-17",{"date":67,"type":20},{"date":69,"type":20},{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":4},"100610657","ai-assisted-bronchoscopy-navigation-and-diagnostic-system-for-severe-pneumonia-a-multicenter-prospective-study-100610657","NCT07230431","AI-Assisted Bronchoscopy Navigation and Diagnostic System for Severe Pneumonia: A Multicenter Prospective Study","Development and Clinical Validation of an Embodied-Intelligence-Assisted Bronchoscopy Navigation and Diagnostic System: A Multicenter Prospective Study","EIBRONCH","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Severe pneumonia requiring clinically indicated bronchoscopy for diagnosis and\u002For therapy, as determined by the treating team.\n3. Written informed consent from the patient or a legally authorized representative.\n4. Expected to tolerate bronchoscopy with current respiratory support (e.g., HFNC\u002FNIV\u002FIMV) per site protocol\n\nExclusion Criteria:\n\n1. Standard contraindications to bronchoscopy, such as uncontrolled hypoxemia despite support (SpO2 \\\u003C90% for ≥30 s on FiO2 ≥0.60), hemodynamic instability requiring escalating vasopressors, or malignant arrhythmia not controlled.\n2. Uncorrected coagulopathy likely to increase bleeding risk (e.g., platelets \\\u003C50×10\\^9\u002FL or INR \\>1.5) per site policy.\n3. Known pregnancy or breastfeeding if the investigator judges risk outweighs benefit according to site policy.\n4. Participation in another interventional drug\u002Fdevice study that could interfere with outcomes.\n5. Any condition that, in the investigator's judgment, makes participation unsuitable (e.g., emergent life-saving bronchoscopy without time for consent).",{"count":101,"type":20},100,[23],"This study will evaluate an embodied-intelligence-assisted bronchoscopy navigation and diagnostic system for patients with severe pneumonia who require clinically indicated bronchoscopy. The system provides real-time visual cues and voice prompts to help physicians localize target lung segments and describe endobronchial findings; physicians remain fully responsible for all clinical decisions. The trial is designed as a prospective, multicenter, controlled study conducted at about ten hospitals in China, with an anticipated sample size of approximately 100 patients. The primary objective is to determine whether AI assistance improves diagnostic agreement compared with the reference assessment, while secondary objectives include navigation success (e.g., loss-of-path rate), procedure time, and complication rates. The results will provide evidence on the safety and effectiveness of AI-assisted bronchoscopy and support product validation and registration.",[105,106],"Respiratory Failure (Pediatric Patients)","Pneumonia",[108,109,110,111,112,113],"Severe pneumonia","Bronchoscopy","Navigation system","Artificial intelligence","Computer-assisted","Diagnostic support","2025-11-13",{"date":116,"type":35},"2025-11-17",{"date":118,"type":20},"2025-11",{"date":120,"type":20},"2026-11",{"name":41,"class":42},{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100566924","an-observational-clinical-study-on-the-construction-of-an-artificial-neural-network-model-for-icu-pneumonia-100566924","NCT06661499","An Observational Clinical Study on the Construction of an Artificial Neural Network Model for ICU Pneumonia","An Observational Clinical Study on the Construction of an Artificial Neural Network Model for Rapid Intelligent Diagnosis of Microorganisms in ICU Pneumonia Based on Species-specific Rapid Detection of Pathogenic Bacteria","Inclusion Criteria:\n\n1. aged ≥18 years;\n2. agreed to obtain lower respiratory specimens for rapid testing of pathogenic bacteria;\n3. all were enrolled by an experienced physician who dynamically determined that the microorganisms were in a colonised or infected state;\n4. signed an informed consent form.\n\nExclusion Criteria:\n\n1. pregnant women;\n2. lactating women;\n3. patients who could not obtain lower respiratory specimens;",{"count":130,"type":20},600,"OBSERVATIONAL","To achieve rapid, intelligent and accurate microbiological diagnosis and treatment for ICU pneumonia, an artificial neural network model for microbiological diagnosis is established, which depends on many clinical cases and machine deep learning from clinical experts' judgements according to species-specific rapid detection of pathogenic bacteria and other clinical parameter variables of patients.",[106],[135,136,137,138,139],"pneumonia","colonization","infection","artificial neural network model","intensive care unit","2024-10-24",{"date":142,"type":35},"2024-10-28",{"date":144,"type":20},"2025-01",{"date":146,"type":20},"2027-12",{"name":41,"class":42},1,""]